An erectile dysfunction drug that reduces by half the time patients need to take the pill has been approved by the U.S. Food and Drug Administration.» Read More
A U.S. Senate panel asked the Centers for Disease Control and Prevention to explain the breach that exposed many to live anthrax, a deadly pathogen.
Vertex's Kalydeco was the first medicine to address the underlying genetic cause. A new drug combination, Kalydeco and Lumacaftor, is designed to treat many additional cases.
Allergan advised investors not to sell their shares to Valeant, which launched a hostile takeover offer for the Botox maker last week.
Genetics startup 23andMe said it is one step closer to resuming sales of its full-fledged health product.
Researchers have discovered that an FDA-approved arthritis drug may hold the secret to curing hairlessness.
Basically, the patient makes his own drug, says Stephane Bancel, Moderna Therapeutics CEO explaining how his company is revolutionizing mRNA technology.
CNBC's Julia Boorstin takes a look at how Moderna Therapeutics is disrupting the biotech world.
CNBC's Jim Cramer gives his call on the "only really legitimate marijuana stock" in the market and a food company.
US Agriculture Secretary is confident an approved vaccine would help fight a deadly virus that has killed millions of pigs.
Valeant said it plans to launch an exchange offer to Allergan shareholders this week, soliciting proxies to call for a meeting to discuss its offer.
Shire has hired investment bank Citi as an adviser following a wave of deals in the healthcare sector.
Medtronic's $43 billion Covidien deal may signal future medical-device company mergers.
Medtronic is buying Covidien in a $42.9 billion agreement that could increase concerns about the rush of U.S. companies striking deals to cut their tax bills.
Many of the world's biggest drugmakers will gather starting Friday in San Francisco for the American Diabetes Association's annual meeting. Here's what investors need to know.
Orexigen Therapeutics shares fell 15 percent after the FDA delayed its decision on the drug pending post-marketing safety monitoring requirements.
Orexigen Therapeutics said the FDA delayed a decision on its obesity drug by three months, sending the company's shares down about 19 percent.
Baupost Group appears to have made a nearly $1 billion off of Merck's deal to buy Idenix.
Achillion's been a takeover target for years. But Merck's acquisition of Idenix may mean Achillion's time has come.
Allergan's board of directors announced on Tuesday that it has unanimously rejected a revised, unsolicited buyout offer from Valeant Pharmaceuticals.
Analysts say there's more to Merck's interest in Idenix than its drug portfolio: intellectual property. And that's why Gilead's shares are lower.
Get the best of CNBC in your inbox